Human monoclonal antibody against group A red blood cells

• US 4,764,465 A
• Filed: 09/30/1986
• Issued: 08/16/1988
• Est. Priority Date: 04/26/1984
• Status: Expired due to Fees

• Current Assignee: Cetus Oncology Corporation (Novartis Ag)
• Original Assignee: Cetus Corporation (Novartis Ag), Board of Trustees of the Leland Stanford Junior University (Stanford University)
• Inventors: Foung, Steven K. H., Grumet, F. Carl, Engleman, Edgar G., Larrick, James W., Raubitschek, Andrew R.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Graeter, Janelle
• Application Number:
  US06/913,638
• Time in Patent Office: 686 Days
• Field of Search: 436/520, 436/548, 435/7, 435/68, 435/172.2, 435/240, 435/241, 935/81, 935/89, 935/96, 935/99, 935/102, 935/106, 935/110, 424/11
• US Class Current: 435/70.21
• CPC Class Codes: C07K 16/34 against blood group antigens
• CPC Class Codes: C12N 5/166 resulting from interspecies fusion
• CPC Class Codes: G01N 33/569 for microorganisms, e.g. protozoa, bacteria, viruses
• CPC Class Codes: G01N 33/80 involving blood groups or blood types or red blood cells white blood cells G01N33/56972
• CPC Class Codes: Y10S 530/865 Human

Abstract

A human monoclonal antibody that directly agglutinates type A human red blood cells is described. The exemplified antibody is an IgM and is produced by hybrid cells lines S-H22 and HHA1. The antibody is useful as an ABO typing reagent.

Claims

1. A trioma cell line capable of secreting a human monoclonal antibody specific against A red blood cell antigen, said cell line comprising

a fusion partner produced by fusing mouse myeloma cells and non-malignant human B-lymphocytes, selecting fusion products which show stable immunoglobulin secretion and HLA surface antigen production in culture, treating the selected fusion products with a mutagen, and selecting mutagenized fusion products which retain the ability to produce HLA surface antigen, show no immunoglobulin secretion, and are unable to survive in a growth medium which allows growth of a successful fusion product formed by fusing the fusion partner with a human immunoglobulin-secreting B-lymphoid cell, and

fused with a fusion partner, an B-lymphoid cell which is derived from a blood type O human donor, activated with Epstein-Barr virus, and selected for secretion of anti-A red blood cell antibody.

2. The cell line of claim 1, which has the characteristics of ATCC #HB 8518.

3. An anti-A red blood cell antibody secreted by the trioma cell line of claim 1.

4. The antibody of claim 3, which is secreted by the cell line having the characteristics of ATCC #HB 8518.

6. The method of claim 4, wherein the fusion partner has the characteristics of ATCC No HB 8464.

5. A method of producing a human monoclonal antibody which is specific against a red blood cell antigen, comprising

providing a fusion partner produced by fusing mouse myeloma cells and non-malignant human B-lymphocytes, selecting fusion products which show stable immunoglobulin secretion and HLA surface antigen production is culture, treating the selected fusion products with a mutagen, and selecting mutagenized fusion products which retain the ability to produce HLA surface antigen, show no immunoglobulin secretion, and are unable to survive in a growth medium which allows growth of a successful fusion product formed by fusing the fusion partner with a human immunoglobulin-secreting B-lymphoid cell, and

fusing the fusion partner with a B-lymphoid cell which is derived from a blood type O human donor, activated with Epstein-Barr virus, and selected for secretion of anti-A red blood cell antibody, and

selecting fusion products which secrete anti-A red blood cell antibodies.

7. The method of claim 5, wherein the fusion product selected has the characteristics of ATC. #HB 8518.